These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 38007650)

  • 41. Cerebrospinal fluid neurofilament light chain protein levels in subtypes of frontotemporal dementia.
    Landqvist Waldö M; Frizell Santillo A; Passant U; Zetterberg H; Rosengren L; Nilsson C; Englund E
    BMC Neurol; 2013 May; 13():54. PubMed ID: 23718879
    [TBL] [Abstract][Full Text] [Related]  

  • 42. CSF sAPPβ, YKL-40, and neurofilament light in frontotemporal lobar degeneration.
    Alcolea D; Vilaplana E; Suárez-Calvet M; Illán-Gala I; Blesa R; Clarimón J; Lladó A; Sánchez-Valle R; Molinuevo JL; García-Ribas G; Compta Y; Martí MJ; Piñol-Ripoll G; Amer-Ferrer G; Noguera A; García-Martín A; Fortea J; Lleó A
    Neurology; 2017 Jul; 89(2):178-188. PubMed ID: 28592456
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cerebrospinal fluid neurofilament light chain differentiates behavioural variant frontotemporal dementia progressors from non-progressors.
    Eratne D; Keem M; Lewis C; Kang M; Walterfang M; Farrand S; Loi S; Kelso W; Cadwallader C; Berkovic SF; Li QX; Masters CL; Collins S; Santillo A; Velakoulis D;
    J Neurol Sci; 2022 Nov; 442():120439. PubMed ID: 36201960
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effects of Peroral Omega-3 Fatty Acid Supplementation on Cerebrospinal Fluid Biomarkers in Patients with Alzheimer's Disease: A Randomized Controlled Trial-The OmegAD Study.
    Tofiq A; Zetterberg H; Blennow K; Basun H; Cederholm T; Eriksdotter M; Faxén-Irving G; Hjorth E; Jernerén F; Schultzberg M; Wahlund LO; Palmblad J; Freund-Levi Y
    J Alzheimers Dis; 2021; 83(3):1291-1301. PubMed ID: 34420949
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Plasma neurofilament light chain predicts Alzheimer's disease in patients with subjective cognitive decline and mild cognitive impairment: A cross-sectional and longitudinal study.
    Mazzeo S; Ingannato A; Giacomucci G; Manganelli A; Moschini V; Balestrini J; Cavaliere A; Morinelli C; Galdo G; Emiliani F; Piazzesi D; Crucitti C; Frigerio D; Polito C; Berti V; Bagnoli S; Padiglioni S; Sorbi S; Nacmias B; Bessi V
    Eur J Neurol; 2024 Jan; 31(1):e16089. PubMed ID: 37797300
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Moving fluid biomarkers for Alzheimer's disease from research tools to routine clinical diagnostics.
    Zetterberg H; Blennow K
    Mol Neurodegener; 2021 Feb; 16(1):10. PubMed ID: 33608044
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease.
    Mattsson N; Insel PS; Palmqvist S; Portelius E; Zetterberg H; Weiner M; Blennow K; Hansson O;
    EMBO Mol Med; 2016 Oct; 8(10):1184-1196. PubMed ID: 27534871
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Evaluation of Plasma Biomarkers for A/T/N Classification of Alzheimer Disease Among Adults of Caribbean Hispanic Ethnicity.
    Honig LS; Kang MS; Lee AJ; Reyes-Dumeyer D; Piriz A; Soriano B; Franco Y; Coronado ZD; Recio P; Mejía DR; Medrano M; Lantigua RA; Teich AF; Dage JL; Mayeux R
    JAMA Netw Open; 2023 Apr; 6(4):e238214. PubMed ID: 37079306
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Amyloid beta, tau, synaptic, neurodegeneration, and glial biomarkers in the preclinical stage of the Alzheimer's continuum.
    Milà-Alomà M; Salvadó G; Gispert JD; Vilor-Tejedor N; Grau-Rivera O; Sala-Vila A; Sánchez-Benavides G; Arenaza-Urquijo EM; Crous-Bou M; González-de-Echávarri JM; Minguillon C; Fauria K; Simon M; Kollmorgen G; Zetterberg H; Blennow K; Suárez-Calvet M; Molinuevo JL;
    Alzheimers Dement; 2020 Oct; 16(10):1358-1371. PubMed ID: 32573951
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison of CSF neurofilament light chain, neurogranin, and tau to MRI markers.
    Mielke MM; Przybelski SA; Lesnick TG; Kern S; Zetterberg H; Blennow K; Knopman DS; Graff-Radford J; Petersen RC; Jack CR; Vemuri P
    Alzheimers Dement; 2021 May; 17(5):801-812. PubMed ID: 33663022
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Synaptic biomarkers in the cerebrospinal fluid associate differentially with classical neuronal biomarkers in patients with Alzheimer's disease and frontotemporal dementia.
    Das S; Goossens J; Jacobs D; Dewit N; Pijnenburg YAL; In 't Veld SGJG; Teunissen CE; Vanmechelen E
    Alzheimers Res Ther; 2023 Mar; 15(1):62. PubMed ID: 36964594
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The Underestimated Relevance of Alzheimer's Disease Copathology in Amyotrophic Lateral Sclerosis.
    Barba L; Otto M; Abu-Rumeileh S
    J Alzheimers Dis; 2023; 95(4):1401-1404. PubMed ID: 37807784
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Higher levels of neurofilament light chain and total tau in CSF are associated with negative outcome after shunt surgery in patients with normal pressure hydrocephalus.
    Braun M; Bjurnemark C; Seo W; Freyhult E; Nyholm D; Niemelä V; Blennow K; Zetterberg H; Fällmar D; Kultima K; Virhammar J
    Fluids Barriers CNS; 2022 Feb; 19(1):15. PubMed ID: 35164790
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Serum Neurofilament Light Chain in the Diagnostic Evaluation of Patients with Cognitive Symptoms in the Neurological Consultation of a Tertiary Center.
    Lopes das Neves P; Durães J; Silva-Spinola A; Lima M; Leitão MJ; Tábuas-Pereira M; Santana I; Baldeiras I
    J Alzheimers Dis; 2023; 95(2):391-397. PubMed ID: 37545232
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Blood and cerebrospinal fluid neurofilament light differentially detect neurodegeneration in early Alzheimer's disease.
    Andersson E; Janelidze S; Lampinen B; Nilsson M; Leuzy A; Stomrud E; Blennow K; Zetterberg H; Hansson O
    Neurobiol Aging; 2020 Nov; 95():143-153. PubMed ID: 32810755
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A Novel Neurofilament Light Chain ELISA Validated in Patients with Alzheimer's Disease, Frontotemporal Dementia, and Subjective Cognitive Decline, and the Evaluation of Candidate Proteins for Immunoassay Calibration.
    Das S; Dewit N; Jacobs D; Pijnenburg YAL; In 't Veld SGJG; Coppens S; Quaglia M; Hirtz C; Teunissen CE; Vanmechelen E
    Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35806226
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Neurofilament light as a biomarker of axonal degeneration in patients with mild cognitive impairment and Alzheimer's disease.
    Chen Y; Therriault J; Luo J; Ba M; Zhang H; Initiative ADN
    J Integr Neurosci; 2021 Dec; 20(4):861-870. PubMed ID: 34997710
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Revisiting the Cerebrospinal Fluid Biomarker Profile in Idiopathic Normal Pressure Hydrocephalus: The Bologna Pro-Hydro Study.
    Abu-Rumeileh S; Giannini G; Polischi B; Albini-Riccioli L; Milletti D; Oppi F; Stanzani-Maserati M; Capellari S; Mantovani P; Palandri G; Cortelli P; Cevoli S; Parchi P
    J Alzheimers Dis; 2019; 68(2):723-733. PubMed ID: 30883350
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Association of Cerebrospinal Fluid Neurofilament Light Concentration With Alzheimer Disease Progression.
    Zetterberg H; Skillbäck T; Mattsson N; Trojanowski JQ; Portelius E; Shaw LM; Weiner MW; Blennow K;
    JAMA Neurol; 2016 Jan; 73(1):60-7. PubMed ID: 26524180
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cost-effectiveness of the use of biomarkers in cerebrospinal fluid for Alzheimer's disease.
    Valcárcel-Nazco C; Perestelo-Pérez L; Molinuevo JL; Mar J; Castilla I; Serrano-Aguilar P
    J Alzheimers Dis; 2014; 42(3):777-88. PubMed ID: 24916543
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.